Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Solvay Pharmaceuticals
• Collaborators: H. Lundbeck A/S; Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder

• Body weight of 100-250 lbs

• Male or females

• 18-55 years of age

Exclusion Criteria:

• Subjects who are acutely psychotic

• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide